TCTMD -- STOCKHOLM, Sweden—Patients who experience bleeding while on prolonged dual antiplatelet therapy are more likely to suffer adverse events and/or discontinue clopidogrel. The findings, presented Sunday, August 29, 2010, at the European Society of Cardiology (ESC) Congress, suggest that physicians should carefully assess bleeding risk before deciding to implant a drug-eluting stent (DES).
